Education
About Us
Working with TipRanks
Follow Us
Regeneron Pharmaceuticals (REGN)
:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$642.00 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)958.04K
Market Cap
$76.56B
Enterprise Value$74.99B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.98B
Price to Earnings (P/E)18.3
Beta0.63
Next Earnings
May 01, 2025EPS Estimate
9.55Last Dividend Ex-Date
Feb 20, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)38.28
Shares Outstanding107,507,540
10 Day Avg. Volume841,520
30 Day Avg. Volume958,041
Standard Deviation0.09
R-Squared0.00224
Alpha0.01
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)N/A
Price to Sales (P/S)5.39
Price to Cash Flow (P/CF)15.20
P/FCF Ratio15.00
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.13
Enterprise Value/Ebitda15.59
Forecast
1Y Price Target
$958.60Price Target Upside37.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Dividend PolicyRegeneron announced plans to start paying dividends, which contributed to a positive movement in the stock price.
Financial OutlookAnalyst recommends upgrading REGN shares from Market Perform to Outperform, indicating a strong positive outlook for the stock.
Bears Say
Competitive PressureConcerns exist that consensus earnings per share could be at risk from faster-than-expected Eylea erosion, impacting near-term performance.
---
Ownership Overview
1.94% Insiders
30.91% Mutual Funds
19.43% Other Institutional Investors
22.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron Pharmaceuticals’s price range in the past 12 months?
Regeneron Pharmaceuticals lowest stock price was $642.00 and its highest was $1211.20 in the past 12 months.
What is Regeneron Pharmaceuticals’s market cap?
Regeneron Pharmaceuticals’s market cap is $76.56B.
When is Regeneron Pharmaceuticals’s upcoming earnings report date?
Regeneron Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 61 days.
How were Regeneron Pharmaceuticals’s earnings last quarter?
Regeneron Pharmaceuticals released its earnings results on Feb 04, 2025. The company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.282 by $0.788.
Is Regeneron Pharmaceuticals overvalued?
According to Wall Street analysts Regeneron Pharmaceuticals’s price is currently Undervalued.
Does Regeneron Pharmaceuticals pay dividends?
Regeneron Pharmaceuticals pays a Notavailable dividend of $0.879 which represents an annual dividend yield of N/A. See more information on Regeneron Pharmaceuticals dividends here
What is Regeneron Pharmaceuticals’s EPS estimate?
Regeneron Pharmaceuticals’s EPS estimate is 9.55.
How many shares outstanding does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has 107,507,540 shares outstanding.
What happened to Regeneron Pharmaceuticals’s price movement after its last earnings report?
Regeneron Pharmaceuticals reported an EPS of $12.07 in its last earnings report, beating expectations of $11.282. Following the earnings report the stock price went up 4.53%.
Which hedge fund is a major shareholder of Regeneron Pharmaceuticals?
Currently, no hedge funds are holding shares in REGN
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$958.60 (37.19% Upside)
$958.60 (37.19% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 28.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.15%
12-Months-Change
Fundamentals
Return on Equity
15.03%
Trailing 12-Months
Asset Growth
14.25%
Trailing 12-Months
Company Description
Regeneron Pharmaceuticals
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Regeneron's strong financial performance, driven by key products and a robust pipeline. However, challenges such as competitive pressure on EYLEA and increased R&D expenses were noted. The company's strategic capital allocation and pipeline advancements position it well for future growth.Read More>---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$958.60
▲(37.19% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
13/19 ratings generated profit
1 Year Average Return
+13.56%
upgraded a buy rating 24 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +13.56% per trade.
---